Skip to main content

Table 3 LV and RV Functional Parameters Compared by Patient Age for T0, T1, and T2a

From: Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer

Parameter

T0

T1

T2

< 50 y

(n = 30)

50-59 y

(n = 25)

≥60 y

(n = 11)

P Value

< 50 y

(n = 30)

50-59 y

(n = 25)

≥60 y

(n = 11)

P Value

< 50 y

(n = 30)

50-59 y

(n = 25)

≥60 y

(n = 11)

P Value

EF, %

64.16

(4.14)

65.56

(4.65)

66.50

(4.75)

.17

61.53

(4.51)

61.70

(5.68)

61.38

(10.93)

.99

59.81

(3.73)

60.19

(6.44)

60.80

(5.54)

.052

LV longitudinal

S, %

−18.34

(2.85)

−17.69

(2.86)

− 17.31

(2.34)

.39

−16.82

(2.74)

− 14.35

(2.79)b

− 14.77

(2.53)b

.007

− 17.03

(3.27)

− 15.33

(2.71)b

−15.06 (2.79)b

.009

SRs, l/s

−1.05 (0.17)

−1.08

(0.18)

− 1.03

(0.15)

.58

− 1.09

(0.19)

−0.97

(0.22)

−1.00

(0.25)

.12

−1.03

(0.16)

−0.99

(0.18)

− 0.92

(0.19)

.22

SRe, l/s

1.16

(0.29)

1.06

(0.26)

1.02

(0.22)

.14

1.11

(0.25)

1.00

(0.28)

1.04

(0.37)

.35

1.13

(0.29)

1.00

(0.22)

0.84

(0.26)b

.009

LV circumferential

S, %

−23.02

(3.48)

−22.81

(4.58)

−24.13

(5.21)

.56

−21.52

(3.76)

−20.47

(3.53)

− 22.02

(4.47)

.40

− 20.21

(4.31)

−19.71

(4.88)

− 23.26 (3.66)

.08

SRs, l/s

−1.51

(0.28)

−1.73

(0.36)

− 1.61

(0.52)

.11

− 1.42

(0.26)

−1.36

(0.30)

− 1.41

(0.38)

.05

− 1.32

(0.32)

−1.34

(0.35)

− 1.54

(0.45)

.20

SRe, l/s

1.57

(0.34)

1.75

(0.54)

1.50

(0.51)

.18

1.46

(0.40)

1.49

(0.35)

1.49

(0.47)

.96

1.34

(0.32)

1.39

(0.43)

1.53

(0.56)

.43

LV radial

S, %

41.52

(12.58)

35.09

(13.13)

38.83

(11.18)

.16

37.73

(13.92)

38.65

(10.35)

37.32

(13.53)

.90

38.13

(13.09)

35.58

(12.55)

35.91

(11.51)

.74

SRs, l/s

2.41

(0.82)

2.82

(2.67)

2.29

(0.76)

.52

2.08

(0.62)

2.33

(0.63)

2.24

(0.78)

.38

2.03

(0.69)

2.15

(0.95)

1.82

(0.64)

.51

SRe, l/s

−2.53

(1.12)

−2.31

(0.85)

−2.14

(1.05)

.41

− 2.10

(0.69)

− 2.41

(0.99)

−2.24

(1.00)

.45

−2.18

(0.93)

− 2.25

(1.12)

−1.92

(0.95)

.66

RV longitudinal

S, %

−23.95

(7.82)

−22.14

(3.95)

− 20.61

(3.25)

.31

−18.87

(5.86)

− 16.85

(4.74)

− 16.54

(5.15)

.36

− 19.54

(5.22)

− 18.37

(5.47)

− 17.96 (4.24)

.58

SRs, l/s

−1.42

(0.38)

− 1.44

(0.34)

− 1.31

(0.16)

.61

− 1.24

(0.28)

−1.20

(0.26)

− 1.21

(0.32)

.89

− 1.35

(0.35)

−1.19

(0.37)

− 1.25

(0.21)

.22

SRe, l/s

1.53

(0.39)

1.51

(0.40)

1.27

(0.37)

.056

1.37

(0.37)

1.21

(0.36)

0.96

(0.38)b

.04

1.30

(0.43)

1.21

(0.40)

1.29

(0.43)

.75

  1. Abbreviations: EF ejection fraction, LV left ventricular, RV right ventricular, S strain, SRe peak early diastolic strain rate, SRs peak systolic strain rate, T0 baseline (pretreatment), T1 time from start of chemotherapy to first echocardiogram, T2 time from start of chemotherapy to second echocardiogram. (SD)
  2. aData are expressed as mean (±SD)
  3. bP < .05 vs age < 50 years
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us